Pulmonx Corporation

NASDAQ:LUNG

Medical - Devices

Healthcare
$2.69 +3.60%

+$0.05 today

Market cap
$117.15M
Beta
0.28
P/E (TTM)
-1.0
EPS (TTM)
-$1.27
52W Low $1.13High $3.88

Volume 0.48M

Average 0.44M

LUNG Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Pulmonx CorporationNASDAQ: LUNG

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows in line with its trailing trend

Q1 FY2026 weighted avg shares of 41.9M shares rose 4.9% year over year, in line with the +4.5% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 1.2% from the prior quarter. Over 3 fiscal years it compounded at +3.1% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +4.9% holds above the trailing-twelve-month pace of +4.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
41.9M+1.2% QoQ
Last fiscal yearDec 2025
40.69M+4.0% YoY
LTMMar 2026
41.11M+4.5% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.9%——
1 year+4.0%——
3-year CAGR+3.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
40.69M USD
Year-over-year change
+4.0%
4-year CAGR
+3.0%

Weighted Avg Shares vs competitors

How LUNG compares with its peers on the latest reported figures

  • LUNG's LTM Mar 2026 weighted avg shares of 41.11M shares is the 7th highest of the 10 companies compared; the peer median is 52.94M shares.
  • Its year-over-year change of +4.5% is the 7th highest of 10, against a peer median of +14.5%.
  • Over three fiscal years its annual growth of +3.1% compares with a peer median of +20.7%.
LUNG Competitors Peer median
Weighted Avg Shares for LUNG and competitors
Company Period LTM YoY 3-year CAGR
VXRTVaxart, Inc.LTM Mar 2026232.05M +14.5%-22.1%
TCRXTScan Therapeutics, Inc.LTM Mar 2026129.84M +7.6%+75.4%
HYPRHyperfine, Inc.LTM Mar 202687.25M +18.9%+10.2%
RLMDRelmada Therapeutics, Inc.LTM Mar 202655.31M +82.9%+10.0%
TELATELA Bio, Inc.LTM Jun 202652.94M +36.3%+42.4%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 202652.9M +2.4%+4.8%
LUNGPulmonx CorporationLTM Mar 202641.11M +4.5%+3.1%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 202638.56M +2.3%+20.7%
IMUXImmunic, Inc.LTM Mar 202619.58M +98.7%+69.8%
ASRTAssertio Holdings, Inc.LTM Mar 20266.42M +0.9%+26.9%
Peer median (excluding LUNG) 52.94M+14.5%+20.7%

Competitors are the stored peer set for LUNG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue48.42M53.66M68.68M83.79M90.5M
Cost of Revenue12.79M13.8M17.92M21.79M23.36M
Gross Profit35.63M39.87M50.75M62M67.14M
Gross Margin73.6%74.3%73.9%74.0%74.2%
Research & Development13.06M15.4M18.08M17.57M19.49M
Selling, General & Admin69.87M83.11M94.61M102.14M101.31M
Operating Expenses82.93M98.5M112.69M119.71M120.8M
Depreciation & Amortization867K1.51M1.95M1.59M1.05M
EBITDA(46.62M)(55.99M)(55.09M)(50.79M)(49.17M)
EBITDA Margin-96.3%-104.3%-80.2%-60.6%-54.3%
Operating Income(47.3M)(58.64M)(61.94M)(57.7M)(53.66M)
Operating Margin-97.7%-109.3%-90.2%-68.9%-59.3%
Interest Income400K1.53M5.57M5.06M2.65M
Interest Expense829K1.07M3.23M3.51M3.16M
Other Income / Expenses(1.01M)67K1.66M1.81M286K
Income Before Tax(48.32M)(58.57M)(60.27M)(55.89M)(53.38M)
Pre-Tax Margin-99.8%-109.1%-87.8%-66.7%-59.0%
Income Tax Expense343K353K571K500K626K
Net Income(48.66M)(58.92M)(60.84M)(56.39M)(54M)
Net Margin-100.5%-109.8%-88.6%-67.3%-59.7%
EPS (Basic)(1.35)(1.59)(1.60)(1.44)(1.33)
EPS (Diluted)(1.35)(1.59)(1.60)(1.44)(1.33)
Weighted Avg Shares36.13M37.1M37.97M39.11M40.69M
Weighted Avg Shares (Diluted)36.13M37.1M37.97M39.11M40.69M

Pulmonx Corporation

NASDAQ:LUNG

Intrinsic Alpha fair value

Locked

Current Price

$2.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.